Table III.

Current society recommendations regarding COVID-19 vaccination

Society	Recommendations
National Psoriasis Foundation33	•All patients with psoriasis should accept a vaccine as soon as it becomes available to them •Psoriasis and/or psoriatic arthritis are not contraindications to vaccination
International Psoriasis Council34	•No specific guidance regarding vaccination •Stated that registry data should be collected to inform whether SARS-CoV-2 vaccines either positively or negatively affect psoriasis outcome
International Pemphigus and Pemphigoid Foundation35	•Patients with autoimmune bullous diseases should be vaccinated when a vaccine is available to them, as these patients are also at high risk for complications of COVID-19 •In most cases, immunosuppressive treatment should not be interrupted to receive a vaccine as this could result in relapse or flare of disease •In patients treated with rituximab, vaccination should be completed 2 weeks prior to the start of rituximab treatment whenever possible, otherwise it is best to wait 4-6 months after the last rituximab infusion
National Eczema Association36	•Atopic dermatitis is not a contraindication to vaccination •Any patients with history of anaphylaxis or reaction to a vaccine ingredient should consult with their allergist prior to vaccination
Hidradenitis Suppurativa Foundation37	•People with HS are not at increased risk for severe COVID-19 due to HS or any subsequent treatment and should be able to safely receive the vaccine when it is available to them •Patients should not stop any biologics in order to receive a vaccine and should speak to their physician regarding any concerns
American College of Rheumatology38,39	•Patients with autoimmune and inflammatory rheumatologic disease should be prioritized for vaccination •For patients with rheumatologic conditions, the theoretical risk of disease flares due to COVID-19 vaccination is outweighed by the definite risk of severe COVID-19 infection •For those with well-controlled disease: recommend to hold methotrexate and JAK inhibitors for one week after each vaccine dose, to hold subcutaneous abatacept 1 week prior to and after the first COVID-19 vaccine dose only, and that patients taking cyclophosphamide should time their infusion to be 1 week after each vaccine dose if possible •In patients treated with rituximab: vaccine series should be initiated 4 weeks prior to the next scheduled cycle, and the next dose be delayed for 2-4 weeks after the second vaccine dose, if the patient's disease activity allows •No recommendation for dose or timing modifications for patients taking oral steroids, hydroxychloroquine, IVIG, apremilast, sulfasalazine, leflunamide, oral cyclophosphamide, azathioprine, TNFi, IL-17 inhibitors, IL-12/23 or IL-23 inhibitors, belimumab, or oral calcineurin inhibitors

HS, Hidradenitis suppurativa; IL, interleukin; IVIG, intravenous immunoglobulin; JAK, janus kinase; TNFi, tumor necrosis factor inhibitor.